Skip to main content
Clinical Trials/NCT05510752
NCT05510752
Not yet recruiting
Phase 3

Cognitive Behavioural Therapy Versus Psychoeducation for Perinatal Anxiety: A Randomized Controlled Trial

St. Joseph's Healthcare Hamilton0 sites216 target enrollmentSeptember 1, 2022

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Perinatal Anxiety
Sponsor
St. Joseph's Healthcare Hamilton
Enrollment
216
Primary Endpoint
State-Trait Inventory for Cognitive and Somatic Anxiety (STICSA)
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

Anxiety during pregnancy and the postpartum (perinatal) period is very common and is associated with adverse consequences for mothers and their infants. Currently, medication is the most commonly prescribed treatment for perinatal anxiety and the lack of nonmedication-based interventions for perinatal anxiety is a barrier to receiving effective treatment for many women. As such, the present single-blind, randomized controlled trial seeks to evaluate whether group-based cognitive behavioural therapy, the gold-standard psychological treatment for anxiety disorders in the general population, effectively treats perinatal anxiety symptoms when compared to a psychoeducation group, which is currently the most commonly prescribed non-medication-based treatment for perinatal distress.

Registry
clinicaltrials.gov
Start Date
September 1, 2022
End Date
September 1, 2026
Last Updated
3 years ago
Study Type
Interventional
Study Design
Factorial
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sheryl Green

Associate Professor, Clinical Psychologist

St. Joseph's Healthcare Hamilton

Eligibility Criteria

Inclusion Criteria

  • Women 18 and older that are pregnant or between 0-12 months postpartum;
  • Principal diagnosis of an anxiety disorder as per the Mini International Neuropsychiatric Interview for DSM-5 (version 7.0.2) with or without comorbid depression;
  • No concurrent psychological treatment;
  • Not taking psychoactive medication or a) medications are stable in dose and type for at least 8 weeks prior to the study (as per Canadian psychiatric guidelines; and b) medications remain stable throughout the study;
  • Fluent in English, minimal grade 8 reading level.

Exclusion Criteria

  • Severe depression/suicidality requiring acute intervention;
  • Women with psychotic or current substance use disorders,
  • medication changes in dose or type or less than 5/6 sessions complete (will continue with treatment but be excluded from the study).

Outcomes

Primary Outcomes

State-Trait Inventory for Cognitive and Somatic Anxiety (STICSA)

Time Frame: Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.

The STICSA is a 21-item self-report scale that assesses cognitive and somatic components of anxiety. The STICSA is comprised of a state scale that measures individuals' current anxiety symptoms, and a trait scale that assesses one's proneness to anxiety, more generally. In the present study, only the trait scale of the STICSA will be used. Items are scored on a 4-point scale ranging from 1 ('not at all') to 4 ('very much so'). The STICSA has demonstrated excellent validity and reliability. A cut-off score of 43 or higher on the STICSA has been suggested for detecting a probable anxiety disorder. The STICSA has been validated for use in clinical samples of adults with anxiety disorders, although not explicitly in perinatal samples.

Secondary Outcomes

  • Penn State Worry Questionnaire (PSWQ)(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Generalized Anxiety Disorder 7 (GAD-7)(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Edinburgh Postnatal Depression Scale (EPDS)(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Worry Behaviors Inventory Perinatal Revised (WBI-P)(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Intolerance of Uncertainty Scale (IUS)(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Perceived Stress Scale (PSS).(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Difficulties in Emotion Regulation Scale (DERS)(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Insomnia Severity Index (ISI).(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Anxiety Sensitivity Index (ASI-3)(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Abbreviated Dyadic Adjustment Scale (ADAS)(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Social Provisions Scale (SPS)(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Illness Intrusiveness Rating Scale (IIRS).(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • World Health Organization Quality of Life Scale (WHOQoL-BREF).(Change from pre-treatment (baseline) to one week post-treatment to and 3-month follow up.)
  • Client Satisfaction Questionnaire (CSQ)(One week post-treatment)

Similar Trials